SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application

This review summarizes how SGLT2 inhibitors and GLP-1 receptor agonists protect the kidneys in diabetes through complementary mechanisms, noting SGLT2 inhibitors are stronger for preserving kidney function and GLP-1 agonists for lowering protein in the urine and heart-vessel events.